EA: Gyn Conferences 2023

CME

Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies: Independent 2023 Conference/Congress Coverage

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: December 13, 2023

Expiration: December 12, 2024

Nicoletta Colombo
Nicoletta Colombo, MD, PhD
Linda R. Duska
Linda R. Duska, MD, MPH
Keiichi Fujiwara
Keiichi Fujiwara, MD, PhD
Alexandra Leary
Alexandra Leary, MD, PhD
Domenica Lorusso
Domenica Lorusso, MD, PhD, Prof
David Scott Miller
David Scott Miller, MD, FACOG, FACS
Kathleen N. Moore
Kathleen N. Moore, MD, MS, FASCO
Ana Oaknin
Ana Oaknin, MD, PhD
Prof Isabelle Ray-Coquard
Prof Isabelle Ray-Coquard, MD, PhD
Brian Slomovitz
Brian Slomovitz, MD, MS, FACOG

Activity

Progress
1 2
Course Completed

References

  1. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145-2158.
  2. Powell MA, Hietanen S, Coleman RL, et al. Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 5503.
  3. Mirza MR, Powell MA, Lundgren C, et al. Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 5504.
  4. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388:2159-2170.
  5. Dostarlimab [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2023.
  6. Monk B, Toita T, JC Wu, et al. Durvalumab in combination with and following chemoradiotherapy in locally advanced cervical cancer: results from the phase international, randomized, double-blind, placebo-controlled CALLA trial. Presented at: 2022 International Gynecologic Cancer Society Annual Meeting; September 29 - October 1, 2022. Abstract O001.
  7. Zamarin D, Deng W, Lankes Heather, et al. Evolution of peripheral and tumor immune parameters as biomarkers of differential sequencing of immune checkpoint blockade and chemoradiotherapy in locally advanced cervical cancer: an NRG Oncology/GOG study. Presented at: 2023 Society of Gynecologic Oncology Annual Meeting; March 25-28, 2023. Abstract 4.
  8. Duska L, Romano K, Holman L, et al. A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer. Presented at: 2023 Society of Gynecologic Oncology Annual Meeting; March 25-28, 2023. Abstract 29.
  9. Slomovitz BM, Deng W, Killion J, et al. GOG 3026 A phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum (LGSOC): a GOG Foundation study. Presented at: 2023 Society of Gynecologic Oncology Annual Meeting; March 25-28, 2023. Abstract 14.
  10. Moore KM, Angelergues A, Konecny GE, et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA5507.
  11. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757-765.
  12. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.
  13. O’Malley DM, Oaknin A, Matulonis UA, et al: Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with bevacizumab in patients with platinum-agnostic ovarian cancer: final analysis. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; Jun 4-8, 2021. Abstract 5504.
  14. Harter P, Trillsch F, Okamoto A, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA5506.
  15. Plante M, Kwon JS, Ferguson S, et al. An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): a Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA5511.
  16. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895-1904.
  17. Monk BJ, Colombo N, Tewari KS, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 5500.
  18. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab in persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021; 385: 1856-1867.
  19. Pérez-Fidalgo JA, Vergote I, Hamilton E, et al. Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study. Presented at: 2023 European Society of Medical Oncology Annual Meeting; September 28 - October 1, 2023. Abstract 265.
  20. Vergote I, Peréz Fidalgo A, Hamilton E, et al. Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting; March 18-21, 2022. Abstract 249.
  21. Moore KN, Makker V, Yeku Oladapo, et al. DB-1303, a HER2-targeting ADC, for patients with recurrent/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1/2a trial. Presented at: 2023 European Society of Medical Oncology Annual Meeting; September 28 - October 1, 2023. Abstract 430.
  22. Lorusso D, Colombo N, Tewari KS, et al. Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: final overall survival results and bevacizumab subgroup analysis of KEYNOTE-826. Presented at: 2023 European Society of Medical Oncology Annual Meeting; September 28 - October 1, 2023. Abstract 67.
  23. Lederman J, McNeish I, Lord R, et al.  ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis. Presented at: 2023 International Gynecologic Cancer Society Annual Meeting; November 5-7, 2023. Abstract Seminal 5.
  24. Clamp AR, McNeish I, Lord R, et al. ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis. Presented at: 2023 European Society of Medical Oncology Annual Meeting; September 28 - October 1, 2023. Abstract 159.
  25. Gonzalez-Martín A, Gladieff L, Tholander B, et a. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin, and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013;49:3831-3838.
  26. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial Lancet Oncol. 2022; 23:919-930.
  27. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14:1020-1026.
  28. Colombo N. Harano K, Hudson E, et al. Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: ENGOT-en7/MaNGO/AtTEnd study. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract LBA40.
  29. Westin S, Moore KN, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed ​by maintenance durvalumab ± olaparib as a ​first-line treatment for newly diagnosed advanced ​or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract LBA41.
  30. Westin S, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2023;[Epub ahead of print].
  31. Joly FL, Leary A, Ray-Coquard I, et al. Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced metastatic endometrial cancer patients. The GINECO randomized phase IIb UTOLA trial. Ann Oncol. 2023(suppl 2):S1283.
  32. Ray-Coquard I, Pignata S, Lee J-Y, et al. First results from the ​ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib or atezolizumab + bevacizumab for persistent/recurrent rare epithelial ovarian cancer. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract 747MO.
  33. Lorusso D, Xian Y, Hasegawa K, et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract LBA38.
  34. McCormack M, Gallardo D, Eminowicz G, et al. A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract LBA8.
  35. McCormack M, Gallardo D, Eminowicz, et al. A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial. Presented at: 2023 International Gynecologic Cancer Society Annual Meeting; November 5-7, 2023. Abstract 0270.
  36. Oaknin A, Gladieff L, Martinez-Garcia J, et al. Primary results from BEATcc (ENGOT-Cx10/ GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab combined with bevacizumab and a platinum doublet for metastatic (stage IVB), persistent or recurrent cervical cancer. Presented at: 2023 European Society of Medical Oncology Virtual Plenary; November 16-17, 2023. Abstract VP5-2023.
  1. Vergote I, González-Martín A, Fujiwara K, et al. innovaTV 301/ENGOT-cx12/GOG-3057:​ a global, randomized, open-label, phase 3 study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract LBA9.
  2. Coleman RL, Lorusso D, Genningens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609-619.
  3. Tewari KS, Mon BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med. 2022;386: 544-555.
  4. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: the phase 3, NRG GY018 Study. Presented at: 2023 International Gynecologic Cancer Society Annual Meeting; November 5-7, 2023. Abstract Seminal 1.
  5. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Presented at: 2023 International Gynecologic Cancer Society Annual Meeting; November 5-7, 2023. Abstract Seminal 2.
  6. Colombo N. Harano K, Hudson E, et al. A Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer: the AtTEnd study. Presented at: 2023 International Gynecologic Cancer Society Annual Meeting; November 5-7, 2023. Abstract Seminal 3.
  7. Westin S, Moore K, Chon HS, et al. DUO-E/GOG-3041/ENGOT-EN10 Trial: carboplatin/paclitaxel + durvalumab followed by maintenance durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Presented at: 2023 International Gynecologic Cancer Society Annual Meeting; November 5-7, 2023. Abstract Seminal 4.
  8. Mirza MR, Sharma S, Herrstedt J, et al. Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: analysis of progression-free survival and overall survival outcomes by molecular clasification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Presented at: 2023 European Society of Medical Oncology Annual Meeting; October 20-24, 2023. Abstract 740MO.